- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03097887
Omega Loop Gastric Bypass With And Without Anti-Reflux Sutures
Prospective, Randomized, Controlled Trial of Omega Loop Gastric Bypass With and Without Anti-reflux Sutures - a Pilot Study
This proposed trial is designed to answer the following questions: First, is biliary reflux to the distal esophagus present before OLGB and does it increase after the procedure? Second, does performing an OLGB with or without anti-reflux sutures make a difference in (biliary) reflux exposures of the distal esophagus? To answer these questions the investigators plan to perform a randomized, controlled trial involving two groups. Group A will undergo an OLGB without anti-reflux sutures and consists of 50 patients. Group B will receive an OLGB with anti-reflux sutures and also consists of 50 patients.
Gastroscopic evaluation for inflammation and reflux will be performed before and one year after the operation utilizing multilevel intraluminal impedance pH-monitoring (MII-pH) and intragastric Bilitec 2000™. Furthermore, the study will be blinded to the patient. Long-term weight loss, the resolution of comorbidities and the incidence of surgical complications will serve as secondary endpoints. Follow-ups will be performed at 3, 6, and 12 months postoperatively to assess all primary and secondary goals.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Obesity, and especially its comorbidities, has unarguably become the number one threat to human health in the modern world. Western lifestyle leads to an increased prevalence and thus to a higher mortality (i.e. due to cardiovascular diseases).
The positive effects of gastric bypass surgery on excess weight loss and comorbidity resolution are well-known. In contrast to the standard laparoscopic Roux-en-Y Gastric Bypass (RYGB), a newer method, the laparoscopic Omega Loop Gastric Bypass (OLGB), has emerged over the past years. It is believed to be the simpler method involving only one anastomosis (instead of two) and therefore potentially reducing morbidity and mortality whilst maintaining comparable excess weight loss. However, since this new type of gastric bypass is similar to the former Billroth II resection (BII), the carcinoma risk is a concern. The OLGB is different from the BII resection in many ways. For instance, it involves creating an approximately 10 cm long narrow gastric pouch which could prevent the suspected underlying pathogenetic mechanism: biliary reflux to the gastric tube and subsequently to the esophagus. Biliary reflux is suspected to stimulate squamous esophageal cells and Barrett's epithelial cells to produce inflammatory mediators and therefore cause oxidative stress, DNA damage and apoptosis which might lead to adenocarcinoma.
Worldwide, there are currently two different ways to perform an OLGB: with or without anti-reflux sutures, which involve sewing the biliopancreatic limb to the staple line of the pouch using V-Loc (non-absorbable) moving upwards as far as easily possible without creating any tension.
This proposed trial is designed to answer the following questions: First, is biliary reflux to the distal esophagus present before OLGB and does it increase after the procedure? Second, does performing an OLGB with or without anti-reflux sutures make a difference in (biliary) reflux exposures of the distal esophagus?
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Daniel M Felsenreich, Dr.
- Phone Number: 56220 +43 1 40400
- Email: moritz.felsenreich@meduniwien.ac.at
Study Contact Backup
- Name: Gerhard Prager, Univ. Prof.
- Phone Number: 54320 +43 1 40400
- Email: gerhard.prager@meduniwien.ac.at
Study Locations
-
-
Vienna
-
Wien, Vienna, Austria, 1090
- Recruiting
- Medical University Vienna
-
Contact:
- Daniel Moritz Felsenreich, Dr.
- Phone Number: 00436767016111 00436767016111
- Email: moritz.felsenreich@meduniwien.ac.at
-
Contact:
- Daniel Moritz Felsenreich
- Phone Number: 00436767016111 00436767016111
- Email: moritz.felsenreich@meduniwien.ac.at
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age between 20 and 70 years
- Body Mass Index ≥ 35.0 kg/m2
- Exclusion of psychological, endocrinological and anesthesiological contraindications
- Willingness to be assigned to either of the two groups
- Follow-up anticipation
- Willingness to attend all follow-up visits
- Written informed consent
Exclusion Criteria:
- recent or ongoing cardiovascular event within the last 6 months (myocardial infarction, acute coronary syndrome, angioplasty or coronary bypass operation, insult),
- pulmonary embolism or thrombophlebitis within the last 6 months, other bariatric procedures, e.g. gastric banding, Sleeve Gastrectomy, etc., cancer of various origins (exceptions: basal cell carcinoma or carcinoma in situ, disease-free over the last 5 years),
- significant anemia or coagulopathy,
- serum creatinin ≥ 1.5 mg/dl.,
- serum bilirubin or phosphatase elevated or ALT above 3 times the upper limit, stomach, biliopancreatic operations, splenectomy or colon resections, gastric or duodenal ulcer within the last 6 months,
- intraabdominal sepsis (except uncomplicated appendicitis or diverticulitis over 6 months prior to the study),
- organ transplantations,
- anamnestic HIV infection, active TBC, active malaria, chronic Hepatitis B or C, liver cirrhosis,
- alcohol or drug addiction (except caffeine, nicotine) in history,
- acute psychiatric disease interfering with the proposed trial,
- other chronic disease which might interfere with the participation.
Also, patients who are pregnant or plan a pregnancy within the following two years as well as patients who have been included in another study, will be excluded.
Note: Exclusion can be performed by a study coordinator at any time.
Hiatal hernia is not considered an exclusion criterion in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Anti-reflux sutures
Omega Loop Gastric Bypass with anti-reflux sutures using V-Loc sewing device.
Biliary reflux measured using Bilitec 2000™.
|
Bariatric/metabolic surgical procedure
Other Names:
The Bilitec 2000™ device will be used to measure the intensity of biliary reflux in the pouch.
Sewing device to perform the anti-reflux sutures.
|
Active Comparator: No anti-reflux sutures
Omega Loop Gastric Bypass without anti-reflux sutures.
Biliary reflux measured using Bilitec 2000™.
|
Bariatric/metabolic surgical procedure
Other Names:
The Bilitec 2000™ device will be used to measure the intensity of biliary reflux in the pouch.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bile Reflux
Time Frame: 1 year
|
The primary goal of this study is to assess, whether the choice of method (OLGB with or without anti-reflux sutures) affects the occurrence or severity of biliary reflux to the gastric pouch.
Biliary exposure will therefore be assessed before and 12 months after the operation utilizing multilevel intraluminal impedance pH-monitoring (MII-pH) and intragastric Bilitec 2000™.
|
1 year
|
Bile Reflux
Time Frame: 1 year
|
The primary goal of this study is to assess, whether the choice of method (OLGB with or without anti-reflux sutures) affects the occurrence or severity of biliary reflux to the gastric pouch.
Extensive biopsies of the gastric pouch and gastroesophageal junction will be taken to prove histological changes due to biliary reflux.
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Inflammation
Time Frame: 1 year
|
Assessing inflammation before and 12 months after surgery using gastroscopy with biopsy.
|
1 year
|
Weight loss
Time Frame: 1 year
|
Measuring excess weight loss (EWL), to reveal any changes in patients' weight
|
1 year
|
BMI loss
Time Frame: 1 year
|
Excess BMI loss (EBMIL), to reveal any changes in patients' BMI
|
1 year
|
Complications by point in time/stage
Time Frame: 1 year
|
Early postoperative complications (occurring within 30 days) Late postoperative complications (occurring after 30 days)
|
1 year
|
Complications by severity
Time Frame: 1 year
|
Moderate complications (not requiring additional surgical intervention) Severe complications (requiring surgical intervention)
|
1 year
|
Resolution of hyperlipidemia
Time Frame: 1 year
|
Collecting evidence for the resolution of hyperlipidemia
|
1 year
|
Resolution of hypertension
Time Frame: 1 year
|
Collecting evidence for the resolution of hypertension
|
1 year
|
Resolution of diabetes
Time Frame: 1 year
|
Collecting evidence for the resolution of diabetes
|
1 year
|
Resolution of sleep apnea
Time Frame: 1 year
|
Collecting evidence for the resolution of sleep apnea
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Gerhard Prager, Univ. Prof., Vienna Medical University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1640/2016
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bile Reflux
-
Shandong UniversityNot yet recruitingArtificial Intelligence | Bile Reflux | TongueChina
-
Xijing Hospital of Digestive DiseasesCompletedGastric Cancer | Helicobacter Pylori Infection | Bile Reflux Gastritis | Intestinal Metaplasia | Precancerous LesionsChina
-
Chinese PLA General HospitalCompletedDyspepsia | Gastroesophageal Reflux Disease | Bile RefluxChina
-
Universitair Ziekenhuis BrusselUnknownAcid Reflux Esophagitis | Non-acid Reflux EsophagitisBelgium
-
Zagazig UniversityCompletedDyspepsia | Heartburn | Bile RefluxEgypt
-
Private Healthcare Institution Clinical Hospital...RecruitingBile Reflux | Ulcer, GastricRussian Federation
-
Xijing Hospital of Digestive DiseasesEnrolling by invitationGastric Cancer | Bile Reflux | Precancerous LesionChina
-
The Catholic University of KoreaWithdrawnStomach Cancer | GastrectomyKorea, Republic of
-
Mackay Memorial HospitalUnknownGastritis | Peptic Ulcer | Helicobacter Pylori Infection | Bile RefluxTaiwan
-
Children's Hospital Medical Center, CincinnatiCompletedBile Acid Synthesis Defect | Inborn Error of Bile Acid Metabolism | Inborn Error of Bile Acid ConjugationUnited States
Clinical Trials on Omega Loop Gastric Bypass
-
FlevoziekenhuisRecruitingObesity | Obesity, Morbid | Bariatric Surgery CandidateNetherlands
-
Nemocnice Břeclav, p.o.UnknownDiabetes Mellitus, Type 2 | Obesity, SevereCzech Republic
-
Slotervaart HospitalAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)UnknownType 2 Diabetes Mellitus | Obesity, MorbidNetherlands
-
Hospital Universitari de BellvitgeInstituto de Salud Carlos IIIEnrolling by invitationDiabetes Mellitus, Type 2 | Bariatric Surgery Candidate | Severe ObesitySpain
-
Puerta de Hierro University HospitalActive, not recruitingPostoperative Complications | Weight Loss | Morbid ObesitySpain
-
Medical University of ViennaUnknown
-
Puerta de Hierro University HospitalEnrolling by invitationPostoperative Complications | Weight Loss | Morbid ObesitySpain
-
Kaunas University of MedicineUnknown
-
Hospital Universitario Virgen de la ArrixacaUnknownObesity | Diabetes MellitusSpain
-
Ain Shams UniversitySuspended